Skip to main content

Advertisement

Table 2 Univariate analysis of factors predictive of recurrence-free and overall survival

From: Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma

Factors No. of patients MDFSTa (95% CI) P value Factors No. of patients MOSTb (95% CI) P value
Gender    0.602 Gender    0.431
 Male 515 42.0 (33.4–53.0)   Male 520 178.0 (98.0–NA)  
 Female 144 34.0 (26.1–71.5)   Female 145 189.0 (67.0–NA)  
Ages (years)    0.167 Ages (years)   0.428
 < 51 274 50.5 (32.4–72.2)   < 42 90 189.0 (64.5–NA)  
 ≥ 51 385 37.5 (28.8–45.6)   ≥ 42 575 178.0 (106.0–NA)  
Hepatitis B or C infection status   0.722 Hepatitis B or C infection status   0.964
 Negative 109 53.0 (37.5–NA)   Negative 110 193.0 (NA–NA)  
 Positive 537 38.0 (30.9–49.7)   Positive 541 120.0 (89.0–NA)  
Platelet count (× 1000/uL)   0.49 Platelet count (× 1000/uL)   0.026
 ≥ 200 165 38.0 (21.6–58.0)   ≥ 294 43 77.5 (29.4–NA)  
 < 200 483 39.1 (33.0–53.0)   < 294 611 178.0 (109.7–NA)  
Serum creatinine (mg/dL)   0.416 Serum creatinine (mg/dL)   0.55
 < 1.2 538 43.4 (34.0–57.9)   < 1.2 542 178.0 (125.3–NA)  
 ≥ 1.2 60 37.5 (20.9–NA)   ≥ 1.2 61 69.5 (61.2–NA)  
Serum albumin (g/dL)   < 0.001 Serum albumin (g/dL)   < 0.001
 < 4.0 297 21.6 (16.0–27.8)   < 4.0 300 64.2 (49.0–89.0)  
 ≥ 4.0 361 69.0 (55.4–102.0)   ≥ 4.0 364 189.0 (178.0–NA)  
Serum total bilirubin (mg/dL)   0.12 Serum total bilirubin (mg/dL) 0.049
 < 1.5 592 40.0 (32.4–53.0)   < 0.8 352 193.0 (102.0–NA)  
 ≥ 1.5 55 28.0 (10.5–69.0)   ≥ 0.8 301 120.0 (83.8–NA)  
Serum AST (U/L)    < 0.001 Serum AST (U/L)   < 0.001
 < 48 397 69.7 (53.0–104.0)   < 46 375 193.0 (193.0–NA)  
 ≥ 48 261 20.0 (15.0–28.0)   ≥ 46 289 59.1 (45.9–67.0)  
Serum ALT (U/L)    < 0.001 Serum ALT (U/L)   < 0.001
 < 44 361 58.0 (43.9–86.1)   < 48 407 189.0 (178.0–NA)  
 ≥ 44 297 29.0 (21.6–38.6)   ≥ 48 257 67.0 (56.2–110.0)  
Prothrombin time (seconds)   < 0.001 Prothrombin time (seconds) < 0.001
 < 12.4 321 63.0 (43.4–118.0)   < 12.9 392 193.0 (NA–NA)  
 ≥ 12.4 327 31.4 (23.2–39.0)   ≥ 12.9 262 88.0 (64.5–NA)  
Indocyanine green retention rate at 15 min 0.001 Indocyanine green retention rate at 15 min 0.852
 < 20.3 525 47.4 (37.5–63.0)   < 12.9 290 178.0 (89.8–NA)  
 ≥ 20.3 112 24.5 (18.0–36.7)   ≥ 12.9 352 120.0 (84.0–NA)  
Child–Turcotte–Pugh classification   < 0.001 Child–Turcotte–Pugh classification < 0.001
 A 606 45.5 (37–58.6)   A 612 178 (125.3–NA)  
 B or C 50 11.9 (6.0–27.7)   B or C 50 14 (9.7–40.2)  
Alpha-fetoprotein (ng/mL)    < 0.001 Alpha-fetoprotein (ng/mL)   < 0.001
 < 12.6 223 53.0 (40.3–109.0)   < 16.8 261 193.0 (193.0–NA)  
 ≥ 12.6 426 30.2 (24.5–44.7)   ≥ 16.8 394 98.0 (67.2–NA)  
Preoperative TACE    0.100 Preoperative TACE    0.017
 No 396 51.0 (35.8–79.0)   No 403 178 (178.0–NA)  
 Yes 232 37.5 (26.2–48.3)   Yes 231 120 (67.2–NA)  
Extent of resection    0.035 Extent of resection    0.0052
 Major 255 31.4 (20.0–47.4)   Major 257 178 (69.5–NA)  
 Minor 404 45.5 (36.79–61.4)   Minor 408 125 (101.0–NA)  
Size of tumor (cm)    < 0.001 Size of tumor (cm)    < 0.001
 < 3.6 282 66.3 (51.0–99.9)   < 5.8 447 189.0 (178.0–NA)  
 ≥ 3.6 377 21.5 (16.0–28.8)   ≥ 5.8 218 46.3 (28.0–83.8)  
Tumor number    0.317 Tumor number    0.259
 Single 520 50.5 (38.6–66.0)   Single 526 189.0 (189.0–NA)  
 Multiple 139 11.5 (8.8–21.6)   Multiple 139 34.7 (24.4–56.2)  
Extent of vascular invasion    < 0.001 Extent of vascular invasion   <0.001
 Group A 326 79.0 (66.3–110.0)   Group A 329 193.0 (178.0–NA)  
 Group B 191 22.4 (19.3–37.2)   Group B 191 73.4 (59.1–114.0)  
 Group C 98 12.7 (8.0–24.5)   Group C 101 67.2 (34.8–NA)  
 Group D 44 4.1 (3.6–7.1)   Group D 44 12.0 (7.1–NA)  
Intrahepatic metastasis    0.001 Intrahepatic metastasis   0.049
 Negative 443 58.0 (45.5–75.2)   Negative 447 189.0 (189.0–NA)  
 Positive 216 14.1 (10.4–20.5)   Positive 218 43.0 (33.2–63.3)  
Histologic grading by Edmondson and Steiner’s classification 0.111 Histologic grading by Edmondson and Steiner’s classification 0.004
 I~II 370 47.4 (37.6–68.9)   Negative 373 178.0 (125.3–NA)  
 III~IV 238 21.9 (16.0–37.4)   Positive 241 71.4 (59.1–110.0)  
Microscopic resection margin    0.065 Microscopic resection margin   0.019
 Negative 572 45.6 (38.0–60.4)   Negative 578 189.0 (119.8–NA)  
 Positive 81 8.8 (6.0–19.3)   Positive 81 28.7 (13.2–NA)  
Cirrhosis    < 0.001 Cirrhosis    < 0.001
 Negative 288 68.9 (43.4–110.0)   Negative 291 193.0 (193.0–NA)  
 Positive 325 30.4 (22.2–39.9)   Positive 328 89.0 (67.0–NA)  
American Joint Committee on Cancer TNM stage < 0.001 American Joint Committee on Cancer TNM stage < 0.001
 I 259 102.0 (72.2-NA)   I 262 202.0 (NA–NA)  
 II 242 31.6 (24.1–47.4)   II 244 98.0 (67.2–NA)  
 III-A 62 8.6 (5.8–21.6)   III-A 63 34.9 (25.6–89.8)  
 III-B 37 4.1 (3.6–11.1)   III-B 37 9.63 (6.8–NA)  
 III-C 53 8.0 (4.6–14.1)   III-C 53 18.4 (12.9–83.8)  
 IV-A 6 9.3 (7.8–NA)   IV-A 6 16.0 (4.67–NA)  
LCSGJ TNM stage    < 0.001 LCSGJ TNM stage    < 0.001
 I 76 66.0 (51.0–NA)   I 77 NA (NA–NA)  
 II 324 58.6 (45.5–94.4)   II 325 202.0 (202.0–NA)  
 III 177 20.0 (13.9–39.1)   III 179 64.5 (43.0–178.0)  
 IV-A 69 5.6 (3.6–9.2)   IV-A 70 13.8 (9.0–27.9)  
  1. CI confidence interval, NA not available, TNM tumor node metastasis, LCSGJ the Liver Cancer Study Group of Japan
  2. aMedian disease-free survival time (month)
  3. bMedian overall survival time (month)